Chimerix, Inc.
NASDAQ:CMRX
3.47 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Chimerix, Inc. |
Symbool | CMRX |
Munteenheid | USD |
Prijs | 3.47 |
Beurswaarde | 312,078,267 |
Dividendpercentage | 0% |
52-weken bereik | 0.75 - 3.8 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael T. Andriole M.B.A. |
Website | https://www.chimerix.com |
An error occurred while fetching data.
Over Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)